^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) + RAF265 (BRAF inhibitor, VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer
Excerpt:
We tested RAF265 and BEZ-235 for kinase inhibition, growth inhibition and cell-cycle alterations….The combination strongly inhibited proliferation of DTC and MTC cell lines with mutations in RAS, BRAF, PTEN, and RET.
DOI:
10.1158/1078-0432.CCR-11-0933
